Talabostat

Drug Profile

Talabostat

Alternative Names: PT-100; ValboroPro

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator Tufts University School of Medicine
  • Developer Midatech Pharma US
  • Class Antineoplastics; Boronic acids; Dipeptides; Pyrrolidines; Small molecules
  • Mechanism of Action Dipeptidyl peptidase 8 inhibitors; Dipeptidyl peptidase 9 inhibitors; Fibroblast activation protein antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Chronic lymphocytic leukaemia; Malignant melanoma; Neutropenia; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 20 Apr 2017 Discontinued - Phase-I for Solid tumours (Combination therapy) in USA (PO)
  • 20 Apr 2017 Discontinued - Phase-II for Chronic lymphocytic leukaemia (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA (PO)
  • 20 Apr 2017 Discontinued - Phase-II for Malignant melanoma (Combination therapy, Late-stage disease) in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top